[Ip-health] EU Global Health Council Conclusions presented at WHA

Sophie Bloemen Sophie at haiweb.org
Thu May 20 06:18:42 PDT 2010

Today at the World Health Assembly the European Commission and the
Spanish Presidency presented the Council Conclusions on Global Health
that were agreed to on May 10th by the EU member states. 

The Conclusions, which are an official EU position on behalf of the
member states, are very relevant to discussions taking place this week
at the World Health Assembly, especially regarding the discussion on the
Global Strategy and Plan of Action on Public Health, Innovation and
Intellectual Property and the discussion on counterfeits, IMPACT and IP

The Conclusions stress the need for policy coherence, including on trade
and health. 

Some elements of the conclusions relating to the discussions on access &

15. In line with the commitments made on policy coherence for
development (PCD) and in the
framework of the PCD Work Programme, the Council calls on the Commission
and the
Member States to address the major aspects that influence global health
in the five priority
areas of trade and financing, migration, security, food security and
climate change.

16. In this regard the EU should :
a. support third countries, in particular LDCs, in the effective
implementation of
flexibilities for the protection of public health provided for in TRIPs
agreements, in
order to promote access to medicines for all, and ensure that EU
bilateral trade
agreements are fully supportive of this objective;. 

18. As regards to research and evidence based dialogue and action, the
Council calls on the EU
and its Member States to promote effective and fair financing of
research that benefits the
health of all. Towards that aim the EU will ensure that innovations and
interventions produce
products and services that are accessible and affordable. This should be
achieved by the EU
and its Member States through:

a. working towards a global framework for research and development that
addresses the
priority health needs of developing countries and prioritises pertinent
research actions to
tackle global health challenges in accordance with the WHO Global
Research Strategy.

b. increasing research capacities in public health and health systems in
partner countries
and strengthening cooperation between the EU and partner countries in
this respect.

c. exploring models that dissociate the cost of Research and Development
and the prices of
medicines in relation to the Global Strategy and Plan of Action on
Public Health,
innovation and intellectual property, including the opportunities for EU
transfer to developing countries.

d. ensuring that EU public investments in health research secure access
to the knowledge
and tools generated as a global public good and help generate socially
essential medical
products at affordable prices, to be used through rational use.

e. strengthening and balancing the complete health research process of
implementation, access, monitoring and evaluation. International
cooperation, common
platforms of knowledge sharing and exchange of good practices are
essential in this

More information about the Ip-health mailing list